BVNKF:OTCMKTS
Bavarian Nordic A/S
$36.06
0.00%
(0.00) 1D
Oct 8, 3:46:25 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNKF...
Mkt. cap
2.82B
Avg. vol.
14.00
Volume
0.00
52-wk high
$37.22
52-wk low
$27.69
Beta
1.46
Shares outstanding
79.26M
No. of employees
2K
Mkt. cap
2.82B
Avg. vol.
14.00
Volume
0.00
52-wk high
$37.22
52-wk low
$27.69
Beta
1.46
Shares outstanding
79.26M
No. of employees
2K
News stories
From web sources and news partners
Quartz
·
6 minutes ago
Dow futures rise before September CPI report, Q3 bank earnings
FXStreet
·
1 hour ago
Dow Jones recovering? Four keys to watch, Nasdaq at resistance, US CPI in focus today
The Motley Fool
·
14 minutes ago
The S&P 500 Is Dangerously Concentrated in 5 Tech Giants. Are They Still Buys?
Yahoo Finance
·
40 minutes ago
Jim Cramer Says Most of the Market Is Already in a Bear Market Despite S&P 500 Rally
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com